Adcetris

Active Ingredient(s): Brentuximab Vedotin
FDA Approved: * August 19, 2011
Pharm Company: * SEATTLE GENETICS
Category: Cancer

Brentuximab vedotin (INN; trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.[2] The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seattle Genetics in the US.[3&... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Adcetris 50 mg/10.5ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 51144-050

Labeler:

Seattle Genetics, Inc.